Aram Loeb, MD
Urology · Detroit, MINPI 1598015125
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Coloplast accounts for 86.9% of it on its own, with 28 other manufacturers making up the rest. Among urology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $176.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$97K
- Boston Scientific$7K
- Endo Pharmaceuticals Inc.$3K
- Axonics, Inc.$2K
- Antares Pharma, Inc.$393
- Zyla Life Sciences, Inc.$305
- plus $2K from 23 others
What the payments were for
- Consulting fees$45,54441%
- Speaking & faculty fees$3,2403%
- Travel & lodging$39,08335%
- Food & beverage$11,67210%
- Education$12,51511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 291 | $97,359 |
| Boston Scientific | 155 | $7,431 |
| Endo Pharmaceuticals Inc. | 8 | $3,218 |
| Axonics, Inc. | 39 | $1,826 |
| Antares Pharma, Inc. | 29 | $393 |
| Zyla Life Sciences, Inc. | 60 | $305 |
| Neotract Inc. | 6 | $211 |
| Stryker | 2 | $188 |
| Procept Biorobotics Corporation | 2 | $158 |
| Astellas Pharma US Inc | 7 | $127 |
| Endo USA, Inc. | 1 | $112 |
| Tolmar, Inc. | 4 | $91 |
| Rochester Medical Corporation | 2 | $75 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $73 |
| AbbVie(2 entities) | 3 | $73 |
| Teleflex LLC | 3 | $68 |
| Convatec Inc. | 2 | $47 |
| Olympus America Inc. | 3 | $43 |
| Clarus Therapeutics Inc. | 3 | $39 |
| Halozyme Inc | 2 | $37 |
| Rigicon,inc. | 2 | $33 |
| Dentsply IH AB | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Sagent Pharmaceuticals | 1 | $18 |
| Photocure Inc | 1 | $16 |
| Dentsply IH Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Richard Wolf Medical Instruments Corp. | 1 | $14 |
| Ambu Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$92,290
- Axonics$4,364
- XIAFLEX$3,237
- VIRTUE$863
- AMS$750
- GENERAL - THERAPIES$540
- AMS 700$400
- 1788$170
- UroLift$146
- AQUABEAM SYSTEM$140
- GENERAL ERECTILE DYSFUNCTION$121
- Lumenis Pulse 120H$101
How this compares
$112,054 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 40 | $27,710 |
| XyostedTestosterone Enanthate | 29 | $19,994 |
| MyrbetriqMirabegron | 29 | $18,270 |
| Testosterone | 42 | $5,689 |
| Tamsulosin Hcl | 452 | $4,883 |
| Trospium Chloride | 32 | $1,467 |
| Finasteride | 102 | $1,171 |
| Testosterone Cypionate | 25 | $794 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $484 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $398 |
| Oxybutynin Chloride | 13 | $228 |
| Ciprofloxacin Hcl | 34 | $170 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $59 |
| Cephalexin | 23 | $57 |
| Meloxicam | 44 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $32 | $27,71040 claims |
| Antares Pharma, Inc.Xyosted | $393 | $19,99429 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $18,27029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.
Other urology in Detroit
- David LeavittDetroit$59K
- Craig RogersDetroit$25K
- Naveen KachrooDetroit$25K
- Amit PatelDetroit$22K
- Asha JamzadehDetroit$21K
- Firas AbdollahDetroit$20K
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.